Éric Legouffe

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

Thomas Bachelot, C. Bourgier, Claire Cropet et al. · Journal of Clinical Oncology · 2012 · 709 citations · Full text

Medicine, Oncology, Pharmacology +17

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

Jérôme Moreaux, Éric Legouffe, Éric Jourdan et al. · Blood · 2003 · 567 citations · Full text

Life Sciences, Cell Biology, Immunology +14

Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial

Bertrand Godeau, Sylvie Chevret, Bruno Varet et al. · The Lancet · 2002 · 265 citations

Life Sciences, Hematology, Immunology +12

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

Jérôme Moreaux, Friedrich W. Cremer, Thierry Rème et al. · Blood · 2005 · 257 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +12

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Karim Fizazi, Laura Faivre, F. Lesaunier et al. · The Lancet Oncology · 2015 · 238 citations

Medicine, Oncology, Urology +17